Therapy-related acute myeloid leukemia in Non-Hodgkin lymphoma survivors: Risk, survival outcomes and prognostic factor analysis

Authors

Utsav Joshi, Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USAFollow
Adheesh Bhattarai, Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Suman Gaire, Department of Internal Medicine, Mount Sinai Chicago, Chicago, IL, USA
Pravash Budhathoki, Department of Internal Medicine, Bronx care Health System, NY, USA
Vishakha Agrawal, Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Roshan Subedi, Department of Internal Medicine, Unity Hospital, Rochester, NY, USA
Bishesh Sharma Poudyal, Clinical hematology and Bone marrow transplant Unit, Civil Service Hospital, Kathmandu, Nepal
Prajwal Dhakal, Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA
Ronald Sham, Division of Hematology and Clinical Oncology, Rochester General Hospital, Rochester, NY, USA
Vijaya Raj Bhatt, Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA

Abstract

Background: Therapy-related acute myeloid leukemia (tAML) is a serious complication in patients with Non-Hodgkin lymphoma (NHL) exposed to chemotherapy or radiation. This large database study aims to quantify the risk of tAML in NHL, and determine the impact of tAML on overall survival (OS) of patients with NHL. Materials and Methods: Patients diagnosed with NHL and de novo AML from 2009 to 2018 were identified from the Surveillance, Epidemiology, and End Results database. Multiple primary standardized incidence ratio (SIR) sessions of the SEER*Stat software were used to calculate SIR and absolute excess risk of tAML. Overall survival (OS) was evaluated using Kaplan Meier curves and compared using log rank tests. Multivariate analysis was used to study the role of each covariate on OS in patients with tAML. Results: The SIR of tAML was 4.89 (95% CI 4.41-5.41), with a higher incidence of tAML observed for ageyears, NHL prior to 2013 and within 5 years of diagnosis, and those who received chemotherapy. NHL patients with tAML had lower OS than those without tAML (5-year OS 59% vs. 13%, p

Recommended Citation

Joshi, Utsav; Bhattarai, Adheesh; Gaire, Suman; Budhathoki, Pravash; Agrawal, Vishakha; Subedi, Roshan; Poudyal, Bishesh Sharma; Dhakal, Prajwal; Sham, Ronald; and Bhatt, Vijaya Raj (2023) "Therapy-related acute myeloid leukemia in Non-Hodgkin lymphoma survivors: Risk, survival outcomes and prognostic factor analysis," Hematology/Oncology and Stem Cell Therapy: Vol. 17 : Iss. 1 , Article 1.
Available at: https://doi.org/10.56875/2589-0646.1113

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.